HMI-115, a Potential First-in-Class Treatment for Endometriosis, Published Proof-of-Concept Phase II Clinical Trial Results in The Lancet Obstetrics, Gynaecology, & Women's Health - Fidelity
HMI-115, a Potential First-in-Class Treatment for Endometriosis, Published Proof-of-Concept Phase II Clinical Trial Results in The Lancet Obstetrics, Gynaecology, & Women's Health Fidelity
Published: Nov. 6, 2025, 4:32 a.m.
HMI-115, a Potential First-in-Class Treatment for Endometriosis, Published Proof-of-Concept Phase II Clinical Trial Results in The Lancet Obstetrics, Gynaecology, & Women's Health - PR Newswire
HMI-115, a Potential First-in-Class Treatment for Endometriosis, Published Proof-of-Concept Phase II Clinical Trial Results in The Lancet Obstetrics, Gynaecology, & Women's Health PR Newswire
Published: Nov. 6, 2025, 4:08 a.m.
MSN Labs Gets SEC Go-Ahead to Conduct Phase IV Clinical Trial on Elagolix for Endometriosis - Medical Dialogues
MSN Labs Gets SEC Go-Ahead to Conduct Phase IV Clinical Trial on Elagolix for Endometriosis Medical Dialogues
Published: Nov. 1, 2025, 11:55 a.m.
Triple meeting 2025 – early efficacy signs for Quanta | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
Triple meeting 2025 – early efficacy signs for Quanta | ApexOnco - Clinical Trials news and analysis Oncology Pipeline
Published: Oct. 27, 2025, 3:49 p.m.
ESMO 2025: MSD and Eisai’s endometrial cancer combo shows five-year durability - Clinical Trials Arena
ESMO 2025: MSD and Eisai’s endometrial cancer combo shows five-year durability Clinical Trials Arena
Published: Oct. 20, 2025, 1:12 p.m.
Genmab takes its Profound buy into endometrial | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
Genmab takes its Profound buy into endometrial | ApexOnco - Clinical Trials news and analysis Oncology Pipeline
Published: Sept. 16, 2025, 3:39 p.m.
Endometriosis Pain Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight by DelveInsight | Organon, Ironwood Pharma, Mitsubishi Tanabe Pharma Corp, AbbVie/Neurocrine - Barchart.com
Endometriosis Pain Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight by DelveInsight | Organon, Ironwood Pharma, Mitsubishi Tanabe Pharma Corp, AbbVie/Neurocrine Barchart.com
Published: Sept. 3, 2025, 3:30 p.m.
Endometrial Cancer Pipeline Outlook 2025 - Clinical Trials, - openPR.com
Endometrial Cancer Pipeline Outlook 2025 - Clinical Trials, openPR.com
Published: Aug. 20, 2025, 3:46 a.m.
Endometriosis Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Organon, Ironwood Pharma, Mitsubishi Tanabe Pharma Corp, AbbVie/Neurocrine Biosciences - The Globe and Mail
Endometriosis Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Organon, Ironwood Pharma, Mitsubishi Tanabe Pharma Corp, AbbVie/Neurocrine Biosciences The Globe and Mail
Published: Aug. 6, 2025, 1:11 p.m.
(PDF) Effects of standard and low doses of estradiol on markers of endometrial receptivity in frozen-thawed embryo transfer cycles: Double-blind, randomized clinical trial - researchgate.net
(PDF) Effects of standard and low doses of estradiol on markers of endometrial receptivity in frozen-thawed embryo transfer cycles: Double-blind, randomized clinical trial researchgate.net
Published: July 30, 2025, 3:19 a.m.